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EPILEPSYACCOUNTS FOR1%OFTHEglobal burden of disease due todisability, affecting0.5% to1%oftheworld’s population.1 Despite
currently available antiepileptic drugs,
20% to 40%of all patients with epilepsy
remain refractory to medical manage-
ment.2-5 For such patients, epilepsy sur-
gery still remains underused world-
wide.6-8 Few patients are referred for
epilepsy surgery evaluation, and these re-
ferrals commonlyoccur late in thecourse
of their disease, after 20 years of sei-
zures.9-11 Temporal lobe epilepsy is the
most common formof epilepsy12 and the
most likely to be medically refractory.13
Toexamine the evidencebase for sur-
gery for uncontrolled seizures, in 2003
the Quality Standards Subcommittee of
the American Academy of Neurology
(AAN)performeda systematic reviewof
the efficacy and safety of anterior tem-
poral lobe resections.1 Based on 1 ran-
domized trial and24observational stud-
ies, theyfoundthatanteriortemporal lobe
resection reduced theoccurrenceof dis-
abling seizures and improved patients’
quality of life, with “infrequentmorbid-
ity.” Furthermore, they speculated that
the “greater potential for achieving free-
dom from disabling seizures offered by
surgical treatment, as opposed to con-
tinuing pharmacotherapy, may reduce
the risks of long-term mortality.”
Pharmacoresistant epilepsy has been
associatedwith decreased survival with
standardizedmortality ratios (SMRs, cal-
culated as observed mortality in pa-
tients divided by the expected mortal-
ity for amatched general population) as
high as 16.14,15 Patients becoming sei-
zure free after anterior temporal lobe re-
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Context Patients with pharmacoresistant epilepsy have increased mortality com-
pared with the general population, but patients with pharmacoresistant temporal lobe
epilepsy whomeet criteria for surgery andwho become seizure-free after anterior tem-
poral lobe resection have reduced excess mortality vs those with persistent seizures.
Objective To quantify the potential survival benefit of anterior temporal lobe re-
section for patients with pharmacoresistant temporal lobe epilepsy vs continuedmedi-
cal management.
Design Monte Carlo simulation model that incorporates possible surgical complica-
tions and seizure status, with 10 000 runs. The model was populated with health-
related quality-of-life data obtained directly from patients and data from the medical
literature. Insufficient data were available to assess gamma-knife radiosurgery or va-
gal nerve stimulation.
Main Outcome Measures Life expectancy and quality-adjusted life expectancy.
Results Compared with medical management, anterior temporal lobe resection for
a 35-year-old patient with an epileptogenic zone identified in the anterior temporal
lobe would increase survival by 5.0 years (95% CI, 2.1-9.2) with surgery preferred in
100% of the simulations. Anterior temporal lobe resection would increase quality-
adjusted life expectancy by 7.5 quality-adjusted life-years (95%, CI, −0.8 to 17.4) with
surgery preferred in 96.5% of the simulations, primarily due to increased years spent
without disabling seizures, thereby reducing seizure-related excess mortality and im-
proving quality of life. The results were robust to sensitivity analyses.
Conclusion The decision analysis model suggests that on average anterior tempo-
ral lobe resection should provide substantial gains in life expectancy and quality-
adjusted life expectancy for surgically eligible patients with pharmacoresistant tem-
poral lobe epilepsy compared with medical management.
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section have reduced mortality rates
relative to patients continuing to have
seizures, suggesting potential long-
termsurvival benefit.16,17 Although ideal,
a randomized controlled trial compar-
ing long-term survival with and with-
out surgery is unlikely due to issueswith
equipoise and difficulty with blinding
surgery study participants.18 The Na-
tional Institutes ofHealth–funded,mul-
ticenter Early Randomized Surgical Epi-
lepsyTrial,19which randomizedpatients
with early intractable temporal lobe epi-
lepsy to surgical ormedical therapy,was
stopped early because of low enroll-
ment rates. Consequently, we per-
formedadecisionanalysis using aMonte
Carlo simulationmodel to estimate the
effect of anterior temporal lobe resec-
tion vs continued medical manage-
ment on life expectancy and quality-
adjusted life expectancy among patients




The model considers patients with re-
fractory partial seizures (simple partial,
complex partial, secondarily general-
ized tonic-clonic seizures, or all 3), that
are resistant to at least 2 antiepileptic
medications. To determine surgical eli-
gibility, anepileptogenic region in thean-
terior temporal lobe must be identified
through diagnostic evaluation includ-
ing clinical history, electroencephalo-
gram,magnetic resonance imaging, and
functional tests (neuropsychological test,
single-photon emission computed to-
mography or positron emission tomog-
raphy).Mean (SD) age at the timeof epi-
lepsy surgerywas assumed to be 35 (11)
years9,10,20,21 basedon theweightedmean
age of surgically treated patients in pub-
lished studies.Data estimateswere based
on a systematic search of themedical lit-
erature and combined using a random-
effects model22 because of significant
heterogeneity amongstudies (I2!50%).23
Health-related quality-of-life data were
obtained from patients with pharmaco-
resistant temporal lobe epilepsy.
Decision Analytic Model
The Monte Carlo simulation model24
(FIGURE 1) considered only the strate-
gies of temporal lobe resection or con-
tinuedmedicalmanagement. It included
neither gamma-knife radiosurgery be-





complications (eg, noticeable verbal
memory decline, homonymous hemi-
anopsia, orhemiparesis), or short-term
transient complications (eg, postopera-
tive infections or depression).1 Subse-
quentprognosis forcohortsof10000hy-
pothetically identical patients receiving
oneoptionor the otherwas captured as
patientsmovedamongaprespecifiedset
ofhealthstates.Duringeachyearlycycle,
some patients could develop disabling
seizures, defined as seizures that impair
awareness(ie,complexpartialorsecond-
arily generalized seizures)25 or become
seizure free, defined as entirely seizure
freeorhavingonlysimplepartialseizures





abling seizures increasedmortality and
reduced quality of life.
The annual likelihoodofmoving from
one health state to another was mod-
eled using transition probabilities, with
the simulation continuing until all pa-
tients in the cohort died from epilepsy-
related complications, surgical compli-
cations, or unrelated causes. The
probability ofmortalitywas basedon an-
nual age-specific mortality rates ob-
tained fromUS life tables26 thatwere ad-
justed for additional excess mortality
from seizure persistence, relapse, or re-
mission. All analyses were performed
using Microsoft Excel 2000 and Deci-
sionMaker (WinDM2007; TuftsMedi-
cal Center, Boston, Massachusetts).
Data
TABLE 1 presents the base case data es-
timates (see eAppendix for details at
http://www.jama.com).
One-Year Seizure Outcomes After
Temporal LobeResection.Although the
AAN systematic review of studies pub-
lished between 1990 and 1999 pro-
vided seizureoutcomes, it didnot specify
the follow-up intervals required for es-
timating transition rates. Our literature
search yielded 13 studies published af-
ter July 1999 that provided information
on seizure outcome following temporal
lobe resection9,10,27-37; for 1 study, the in-
vestigators provided the primary data.27
Frompooling these 13 studies, the base-
line probability of being free of dis-



























The square on the left represents a decision node, representing the choice between surgery andmedical manage-
ment. The circle is a chance node, representing various possible outcomes after surgery including procedure-
related operative death, permanent long-term surgical complication, transient short-term surgical complication,
or no surgical complication. The brace signifies a subtree that occurs for all branches leading to that brace. Each
subtree enters a Markov process, leading to 1 of 3 health states (disabling seizures, seizure free, or dead). The
Markov cycle represents time as a single year duringwhich the health statemay change. At the end of each branch
is a terminal node that indicates the health state in which patients will begin the next 1-year cycle. The probability
estimates from the literature in Table 1 determine the likelihood of the chance events.
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abling seizures a year after anterior tem-
poral lobe resection was assumed to be
71.9% (95% confidence interval [CI],
69.5%-74.3%).
Long-term Seizure Outcomes Af-
ter Temporal Lobe Resection. Longi-
tudinal studies of patients with anterior
temporal loberesectionshaveshownthat
the seizure status at 1 year after surgery










found that the likelihood of further re-
lapse for patients seizure free at year 10




withpersistent seizure at the endof year
1 followingsurgery, theannualprobabil-
ity of becoming seizure free between
years 1 and 5 was 5.9% (95% CI, 0.9%-
11%)while the probability of becoming
seizure free after year 5 was 2.0% (95%
CI, 0.2%-7.2%).27,28
One-Year Seizure Outcomes After
Medical Management. Limited data
were available regarding the probabil-
ity of becoming seizure free withmedi-
cal management. In the single random-
ized controlled trial comparing anterior
temporal lobe resection vsmedicalman-
agement, the probability of becoming
free of disabling seizures at 1 year with
continued medical management was
8.0% (95% CI, 0%-16%).9
Long-term Seizure Outcomes Af-
ter Medical Management.Aswith sur-
gery, seizure status after medical man-
agement fluctuates over time. No study
exclusively examined the long-term sei-
zure remission and relapse rates among
patientswith pharmacoresistant tempo-
ral lobe epilepsy with medical manage-
ment, but one study reported these out-
comes in intractable epilepsy patients
(including 50% of patients with tempo-
ral lobe epilepsy).38 Among patients sei-
zure free at the end of year 1, the annual
probability of seizure relapsewas 25.4%
(95% CI, 10.9%-46.2%). Similarly,
among patients with persistent seizures
at the end of year 1, the annual prob-
ability of becoming seizure freewas4.7%
(95% CI, 3.0%-7.0%). By applying the
same relative risk reduction as oc-
curredafter surgery,weassumed that this
probability fell to 1.6% (95% CI, 1.0%-
2.3%) beyond year 5.
Surgical Morbidity. Adverse surgi-
cal complications following anterior
temporal lobe resections include neu-
rological deficits (such as noticeable ver-
bal memory decline), postoperative in-
fections, and emotive or behavioral
changes (such as depression). Based on
the definitions used by the AAN re-
port,1 we categorized adverse surgical
complications as either transient (reso-
lution within 3 months) or perma-
nent. TheAAN systematic review1 iden-
tified 7 studies involving 556 patients
that allowed classification, with tran-
sient complications in 8.0% (95% CI,









Becoming seizure free during first year
Medical management9 8.0 (0 to 16) "
Surgery9,10,27-37 71.9 (69.5 to 74.3) Normal
Seizure relapse if seizure free at end of year 1b
Medical management after year 138 25.4 (10.9 to 46.2) Logit
Surgery
From years 1-521,27,28,32,37 5.6 (2.9 to 8.3) Normal
After year 521,27,28,32,37 4.2 (1.6 to 6.8) Normal
Seizure remission if not seizure free at end of yearb
Medical management
From years 1-538 4.7 (3.0 to 7.0) Normal
After year 538 1.6 (1.0 to 2.3) Logit
Surgery
From years 1 to 527,28 5.9 (0.9 to 11) Normal
After year 527,28 2.0 (0.2 to 7.2) Logit
Surgical complications
Surgical mortality1 0.3 (0 to 0.75) "
Permanent complication1 4.0 (2.0 to 6.0) "
Transient complication1 8.0 (6.0 to 10) "
Standardized mortality ratios
Seizure free16,17 1.11 (0.63 to 1.94) Log normal
Not seizure free
Surgery16,17 5.64 (3.49 to 9.09) Log normal
Medical management39-41 5.40 (3.96 to 7.37) Log normal
Preference-Based Quality of Life Scores for Model Health Statesc
Free of disabling seizures
Medical management 0.96 (0.84-1.0) Uniform
Surgery
No surgical complication 0.97 (0.87-1.0) Uniform
Permanent complication 0.77 (0.32-1.0) Uniform
Transient complication 0.96 (0.84-1.0) Uniform
Not free of disabling seizures
Medical management 0.75 (0.38 to 1.0) Uniform
Surgery
No surgical complication 0.78 (0.41 to 1.0) Uniform
Permanent complication 0.66 (0.19 to 1.0) Uniform
Transient complication 0.75 (0.38 to 1.0) Uniform
Transient surgical complication (days of life deducted) 1.5 (0 to 25.0) Uniform
aPooled mean (SD) age from literature, 35 (11) years.
bAnnual probability.
cThe Monte Carlo analysis used a bootstrap sample for the set of quality-of-life estimates from 1 of the 22 patients
assuming a uniform distribution.
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6.0%-10.0%) and permanent compli-
cations in 4.0% (95% CI, 2.0%-6.0%).
Surgical Mortality. No studies re-
viewed in the AAN report or published
subsequentlyhave reportedanysurgical
deaths from temporal lobe resections.
However, of the 556 patients, 2 (0.3%)
deaths unrelated to surgery occurred
within a month of surgery.1 To bias our
model results against surgeryandrecog-










free after temporal lobe resections, stud-
ies have reported SMRs of 1.7 (95% CI,
0.35 to 5.0)16 and of 0 (no deaths).17 Af-
ter assuminganSMRof1.0 for the study







For patients with persistent sei-
zures or seizure relapse after surgery,
pooling 2 studies yielded an SMR of
5.64 (95% CI, 3.49-9.09).16,17 Despite
a large number of studies examining
long-termmortality in patients with in-
tractable epilepsy, no study has exam-
ined the specific SMR of patients with
pharmacoresistant temporal lobe epi-
lepsy eligible for surgery but treated
medically. Therefore, as the closest ap-
proximation, combining studies in
heterogeneous groups of patients with
intractable epilepsy but who had not
undergone epilepsy surgery39-41 yielded
an SMR of 5.40 (95% CI, 3.96-7.37).
Preference-Based Quality-of-Life
Values. To assess individual prefer-
ences for the health outcomes specified
in our model, we interviewed patients
who had previously undergone tempo-
ral loberesectionsatourcenter,using the
standard gamble (see eAppendix at
http://www.jama.com).42,43 These pref-
erence-based quality-of-life values were
then used to adjust life expectancy to
yield quality-adjusted life expectancy.
The protocol was approved by the in-
stitutional review board at the Colum-
bia University Medical Center. Partici-
pantsprovidedwritten informedconsent.
Table 1 reports the means and 95% CIs
for each health state from 22 patients.
Sensitivity Analyses
In sensitivity analyses, the value of each
parameter used in the model was var-
ied over a broad range to determine if
the preferred strategy changed. If the
preferred strategy changed with varia-
tion,we determined the threshold value
for that parameter so that for values
above the threshold, one strategywould
be preferred,while for values below that
threshold, the alternativewould be pre-
ferred. Sensitivity analysis identifies the
most influential or important para-
meters for this analysis, ie, those with
thresholds. Table 1 lists the baseline val-
ues and the range of values over which
we varied that particular parameter.
Our baseline analyses were second-
orderMonteCarlo simulations inwhich
all parameters were varied simulta-
neously usingnormal, log-normal, logit,
or" distributions based on 95%CIs.44,45
Quality-of-life scoreswere sampled from
a uniform distribution. In these analy-
ses, the simulation selected a single-
point estimate for each parameter from
the respective probability distributions
for eachevaluationrun.Simulationswere
repeated 10 000 times to yield a mean
and 95% CI, incorporating the uncer-
tainty surrounding each variable.
RESULTS
Baseline Analysis
Model predictions of being seizure free
5 years and 10 years after anterior tem-
poral loberesectionwereconsistentwith
resultsfrompublishedstudies(FIGURE2).
Themodel suggests that a prototypical
surgically eligible 35-year-old patient
whowouldhavebeenmedically treated
has an average life expectancy of 27.3
years(95%CI,24.1-30.5)comparedwith
a lifeexpectancyof44.3years in thegen-
eral population.Anterior temporal lobe
resectionwould increase lifeexpectancy
by5.0 years (95%CI, 2.1-9.2)with sur-
gery preferred in 100% of the simula-
tions. Anterior temporal lobe resection
would increasequality-adjusted life ex-
pectancy by 7.5 (95%CI, −0.8 to 17.4)
quality-adjustedlife-years(QALYs)with
surgerypreferredin96.5%ofthequality-
of-life simulations (TABLE 2). For a 35-
year-oldpatient, themodel suggests that
anterior temporal lobe resection in-
creased thenumberof seizure-freeyears
by15.0 (95%CI, 9.6-24.6) and reduced




Univariate sensitivity analysis assessed
the stability of the model results to al-
ternative assumptions. Table 2 presents
the model results for 15- to 75-year-
olds with pharmacoresistant temporal
lobe epilepsy for fixed ages. Variation of
each parameter over the ranges speci-
fied inTable 1 did not alter the preferred
strategy.When extending variation fur-
ther to extreme values (eg, 0%-100% for
probabilities, 1-10 for SMR, and 0-1 for
utilities),medical treatment becamepre-
ferred for (1) probability of surgical
mortality exceeding 24% (baseline,




























5 10 15 20
Comparison of Monte Carlo model predictions for the
5-,10-, 15-, and20-year likelihoodsofbeing freeof sei-
zures after surgery (solid line withmean and 95% con-
fidence intervals)with thepublished5-and10-year like-
lihoods (dashed line todisplay the lowestandhighest re-
portedmeans)ofbeingseizurefreeaftersurgery including
studies that couldnotbeused inourmeta-analysis.32,33,35
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0.3%), (2) SMR for disabling seizures
with medical management falling be-
low2.3 (baseline, 5.4), (3) annual prob-
ability of seizure remission with medi-
cal therapy exceeding 79% (baseline,
4.7%), (4) quality of life for “free of dis-
abling seizures after surgery with no
complications” falling below0.58 (base-
line, 0.97; 95% CI, 0.87-1.0), and (5)
quality of life for “not free of disabling
seizures after surgery without compli-
cation” fallingbelow0.30 (baseline, 0.78;




qualityof life forallotherhealthstates in-




surgical complication, ranging from0to
1(ie,surgeryremainedpreferred).Wealso
performedasensitivityanalysis inwhich
allutilitieswere linked ina fixedpropor-
tion.Usingthisapproach,medicaltherapy
waspreferredonly if all surgical quality-
of-life estimates were reduced by a rela-
tivereductionofat least24%.Inthiscase,
the quality of life of having surgery and
beingfreeofseizureswouldbeworsethan
continuedseizureswithmedical therapy.
To explore potential uncertainty
aroundlong-termsurgicalcomplications,
if thequalityof lifewith long-termcom-
plications fromsurgerywereequivalent
tobeingdead(ie,qualityof lifewithper-
manent complication equals 0), on av-
eragesurgerywouldstill improvequality-
adjusted survival by 6.4 (95% CI, −1.6
to 16.2) QALYswith surgery preferred
in 95.2%of the simulations. Extending
this analysis further, we performed a
2-way sensitivity analysis to examine
jointly the probability of developing a
long-term surgical complication along
with the quality of lifewith such a com-
plication (FIGURE 4). Medical therapy
becomes preferred for combinations of
valueswith a high likelihood of a long-
term surgical complication and a low
quality of lifewith sucha complication,
eg, 24% likelihood and 0 quality of life
(equivalent todeath)or100%likelihood
and 0.71 quality of life.
Studies that includeddata onSMRaf-
tersurgerywerelimitedtoameanfollow-




tical to the general population) after 20
years. In this analysis, anterior temporal
lobe resectionwould increase life expec-
tancybyonly1.2years (95%CI,0.8-1.5,
with surgery preferred in 100% of the
simulations) but by 5 QALYs (95% CI,
−7.0 to 19.7, with surgery preferred in
90.8%ofthesimulations)becauseoffewer
years with seizures.
To compare in isolation the effect of
long-term surgicalmorbidity vs seizure-
related morbidity on quality of life, we
assumed no excess mortality associ-
ated with seizures and found that sur-
gery remainedpreferred by 3.9 (95%CI,
−9.0 to 20.4)QALYs (with surgery pre-
ferred in 86.3% of the simulations) be-
cause patients lived longer (no excess
mortality and had more seizure-free
years). Two of the baseline assump-
tions biased our results in favor ofmedi-
cal therapy. If we relaxed those assump-
tions so that the SMR with seizures
following medical therapy equals that
with surgical treatment (5.64 instead of
5.40) and if the yearly likelihood of sei-
zure relapse following surgery be-
comes 0% after 10 years,27 then the ben-
efit of surgery for a prototypical surgical
patient rose to 9.9 years (95% CI, 7.3-
13.4, with surgery preferred in 100%
of the simulations) and 12.9 QALYs
(95% CI, 5.9-22.4, with surgery pre-
ferred in 100% of the simulations).
COMMENT
Studies have reported the effective-
ness of temporal lobe resection since the
1950s,46,47 yet aminority of patients are
being referred to surgery and those
only after an average of 20 years of ill-
ness.9-11,48 For adolescents and young
adults, this delay may be particularly
significant during a critical period in
Table 2. Expected Outcomes of Decision Analysis
Age at Surgery, y
15 25 35 45 55 65 75
Life Expectancy, Estimate (95% Confidence Interval), y
Surgery 48.5 (41.9 to 56.4) 40.3 (34.2 to 47.3) 32.3 (27.0 to 38.5) 24.8 (20.2 to 29.9) 18.2 (14.4 to 22.4) 12.6 (9.6 to 15.9) 8.0 (5.9 to 10.5)
Medical
management
43.9 (40.0 to 47.9) 35.6 (32.0 to 39.2) 27.3 (24.1 to 30.5) 19.6 (16.9 to 22.5) 13.2 (11.0 to 15.5) 8.0 (6.4 to 9.8) 4.4 (3.4 to 5.5)
Incremental
benefit




99.6 99.9 100 100 100 100 100
Quality-Adjusted Life Expectancy, Estimate (95% Confidence Interval), QALYs
Surgery 42.1 (24.3 to 53.1) 35.2 (20.9 to 44.6) 28.4 (17.5 to 36.5) 22.1 (14.3 to 28.3) 16.4 (11.1 to 21.1) 11.5 (7.9 to 15.1) 7.4 (5.1 to 9.9)
Medical
management
33.8 (12.4 to 43.9) 27.3 (10.2 to 35.6) 20.9 (7.9 to 27.7) 15.2 (5.8 to 20.3) 10.2 (4.0 to 13.8) 6.3 (2.5 to 8.7) 3.4 (1.5 to 4.9)
Incremental
benefit




92.5 94.0 96.5 99.3 100 100 100
Abbreviation: QALY, quality-adjusted life year.
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their psychosocial development. Ac-
cordingly, a panel of experts system-
atically reviewed the risks and ben-
efits of anterior temporal lobe resection
for pharmacoresistant temporal lobe
epilepsy and found that surgery re-
sulted in two-thirds of patients becom-
ing free of disabling seizures with im-
proved overall quality of life. Based on
these findings, they recommended that
patients with disabling seizures who
have failed trials of first-line antiepi-
leptic drugs be referred to an epilepsy
surgery center and that appropriate pa-
tients who accept its risks and ben-
efits be offered surgery.1
Our updated systematic review cor-
roborates their results and extends their
findings to quantify the benefits and
risks. Our model suggests that ante-
rior temporal lobe resection for pa-
tients with pharmacoresistant tempo-
ral lobe epilepsy should increase average
life expectancy and quality-adjusted life
expectancy. When compared with the
benefit accrued from other well-
accepted medical interventions,49 the
5.0-year benefit from anterior tempo-
ral lobe resection for typical surgically
eligible patients (mean age, 35-year-
olds) is substantial. For example, elimi-
nating lifelong coronary heart disease
mortality in 35-year-old men or wom-
en50 increases life expectancy by 3.1 to
3.3 years and coronary artery bypass
grafting or "-blocker use after acute
myocardial infarction increases life ex-
pectancy by 0.25 to 1.1 years.51,52
Inclusionofquality-of-lifebenefit from
being seizure free increases the mean
benefit fromsurgery, but the95%CI for
the quality-of-life gain fromsurgery in-
cludes somenegative values for ages 15
through 35 years. This reflected incor-
porating the preferences of 2 patients
who,despitehavinghadgoodoutcomes
aftersurgery, thoughtthat if theyhadhad





to 0.40 comparedwith their quality-of-
life estimates for disabling seizures af-
ter medical management).
In these simulations, the 95%CIs do
not reflect individual outcomes but
Figure 3. Sensitivity Analysis of Resection vs Pharmacotherapy for Epilepsy
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Probability of Seizure Free With Medical
Management Beyond Year 1, %
C
A, Each line represents the quality-adjusted life-years (QALYs) associated with surgery (solid line) or with medical management (dashed line) for 35-year-old patients
varying the surgical mortality rate from 0% to 80%. For any particular surgical mortality rate, the higher line is the preferred treatment of choice. The dot indicates the
base-case value (0.3%), and the dotted vertical line indicates the threshold (24%) at which temporal lobe resection and medical management are equivalent. Anterior
temporal lobe resection is preferred for probabilities below the threshold, and medical management for probabilities above the threshold. B, As the standardized mortality
ratio (SMR) of patients with seizures on medical management increases, the benefit of surgery increases. The threshold is 2.3 (base-case, 5.4). Temporal lobe resection is
preferred for SMR values above the threshold. C, As the annual probability of becoming seizure free with medical management increases, the benefit of surgery decreases.
The threshold is 79% (base-case, 4.7%). Temporal lobe resection is preferred for probabilities below the threshold. D, As the quality of life without seizures following
surgery decreases, the benefit of surgery decreases. The threshold is 0.58 (base-case, 0.97). Temporal lobe resection is preferred for values above this threshold. Note that
at 0.58, the quality of life with medical management and seizures would be better (0.75) than being seizure free after surgery. E, As the quality of lifewith disabling seizure
after anterior temporal lobe resection decreases, the benefit of surgery decreases. The threshold is 0.30 (base-case, 0.78). Temporal lobe resection is preferred for values
above this threshold. Note that this values fall outside of the 95% confidence interval [CI] for patients who have received surgery (0.41-1.0).
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rather uncertainty in the model para-
meters. They should not be inter-
preted as in a study of hypothesis test-
ing but rather as the range of outcomes.
More relevant for interpretation is the
percentage of model simulations in
which one strategy is preferred over the
other. With the quality-of-life simula-
tions, surgery was preferred in more
than 92% of the simulations across all
ages. For the outcome of life expec-
tancy, surgery was preferred in more
than 99% of simulations and the 95%
CIswere entirely positive across all ages.
Why then does this discrepancy be-
tween clinical practice and recommen-
dations for surgical referral exist? A re-
cent survey of neurologists’ views on
epilepsy surgery and medically refrac-
tory epilepsy53 found that responding
neurologists overestimated the likeli-
hood of surgical complications, with
64%believing that the permanent com-
plication rate exceeded 5%. One-third
reported having had a patient with a se-
rious complication after epilepsy sur-
gery, raising the possibility of availabil-
ity bias, overestimating the likelihood
of memorable events because of sever-
ity.54 Neurologists also differed on the
definition of drug-refractory epilepsy:
77% required failure of at least 2 dif-
ferent polytherapy trials, 14% re-
quired failure of 4 ormore, and 19% re-
quired failure of all approved drugs. In
contrast, in a large cohort study of
newly diagnosed patients with epi-
lepsy, only 11% of patients who failed
an appropriate first-line antiepileptic
drug responded to a second drug and
only 3% responded tomultiple drugs.55
Although the consequence of long-
term surgical complication may influ-
ence neurologists (perhaps in part due
to concerns about errors of commis-
sion more so than errors of omission),
only when varying both the probabil-
ity of long-term complication and the
quality of life with complications be-
yond plausible ranges didmedicalman-
agement become preferred. The qual-
ity of life and mortality benefit from
being seizure free with surgery out-
weighed the risk of long-term surgical
complications. Our analysis suggests
that additional research to clarify the
likelihood of and the quality of life dec-
rement from long-term complications
may help inform patient and physi-
cian decision making.
The most critical parameter affecting
survival involved long-termmortality fol-
lowing either treatment. Increasedmor-
tality from pharmacoresistant epilepsy
typically results from epilepsy-related
causes of death such as seizure-induced
accidents (eg, drowning or burns), sta-
tus epilepticus, suicide, and sudden un-
expected death in epilepsy.56,57 In par-
ticular, sudden unexpected death in
epilepsycomprises themajorityofdeaths
in intractable epilepsy, with a reported
incidence of between 2.2 and 9.3 per
1000 patient-years.17,40,58,59 Two studies
have specifically examined late mortal-
ity after anterior temporal lobe resec-
tion.After stratifyingpatientson their sei-
zure outcome after surgery, both found
that after surgery patientswhowere free
from disabling seizures had mortality
rates similar to that of the general popu-
lation (the 95%CI for SMR included 1),
whereas patientswith persistence of sei-
zures despite surgery had SMRs rang-
ing from 4.7 to 7.4.16,17 Combined with
the higher likelihood of seizure remis-
sion with surgery instead of medical
management, this supports the plausi-
bility of improved survival with ante-
rior temporal lobe resection.
However, differences in mortality
based on seizure status may not be due
to surgery but rather some inherent bio-
logical differences due to selection bias
so that patientswhobecame seizure free
after surgery might have had a lower
SMR even without surgery.15 Indirect
evidence linking poor surgical out-
come and epilepsy mortality is pro-
vided by observational studies. Among
patients who had undergone anterior
temporal lobe resection, those with ad-
vanced age at the time of surgery, longer
duration of epilepsy, secondary gener-
alization to tonic-clonic seizures, and
absence of hippocampal sclerosis on
magnetic resonance imaging scan had
a lower likelihood of becoming sei-
zure free.35,60,61 The presence of second-
arily generalized tonic-clonic seizure
has also been associated with in-
creased risk of sudden unexpected
death.62 If secondary generalization to
tonic-clonic seizures was less com-
mon in surgically selected patients than
in those treatedmedically, selection bias
could account for lowermortality in the
observational studies of patients after
surgery. However, in the only random-
ized controlled trial to date, patients
weremore likely to become seizure free
after surgery and the only death that oc-
curred in that study was from sudden
unexpected death in epilepsy of a pa-
tient in the medical treatment group.9
Figure 4. Probability of Long-term Complication After Surgery and the Quality of Life With a
Long-term Surgical Complication
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The line represents threshold values, so that for combinations of values above the line, surgery is preferred and
for those below the line, medical management is preferred. Even if the quality of life with a long-term com-
plication were 0, the probability of a long-term complication would have to exceed 24% (baseline 4%, 95%
confidence interval [CI], 2%-6%) for medical management to be preferred.
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Our study has some notable limita-
tions. First, the decisionmodel does not
consider other interventions such as
gamma-knife radiosurgery because of
limited information on long-term effi-
cacy and safety63 or vagus nerve stimu-
lators because of limited data on effec-
tiveness.64 Second, data in patients with
pharmacoresistant temporal lobe epi-
lepsy receivingmedicalmanagement re-
main sparse, so our estimates of sei-
zure remission and relapsewithmedical
management beyond the first year in-
cluded adults with other types of in-
tractable epilepsy. Even so, the sensi-
tivity analyses suggest that anterior
temporal lobe resection would remain
preferred unless the annual probabil-
ity of seizure remission beyond year 1
exceeded 79% with medical therapy
(baseline, 4.7%).
Third, no study has specifically ex-
amined the SMR of patients with tem-
poral lobe seizures who would be eli-
gible for surgery but instead continued
medical management. Therefore, we
combined the SMRs of pharmacoresis-
tant epilepsy patients (not necessarily
temporal lobe epilepsy) who were un-
dergoing surgical evaluation or await-
ing surgery, declined surgery, were re-
jected for surgery based on evaluation,
or participated in vagus nerve stimu-
lation trials. The sensitivity analysis sug-
gests that surgery would remain pre-
ferred unless the SMR fell below 2.3, a
value considerably lower than that
found in the literature for pharmaco-
resistant epilepsy patients.
Fourth, we elicited preference-based
quality-of-life estimates from a small
groupofpatientswhohadpreviouslyun-
dergone temporal lobe surgery.This per-
spective may be a source of bias. Our
study assessed these patients’ values for
hypothetical states in anattempt tomini-
mizebiasdue topatients’ outcomeswhile
takingadvantageof their experiencewith
the condition and surgery. There are of-
ten systematic differences between the
patientperspective and thegeneralpopu-
lation perspective in preference stud-
ies, and suchdifferenceswould likely en-
hance the value of surgery in analyses.
Sensitivity analyseswere robust to plau-
sible ranges of utility values. However,
when we extended variation of indi-
vidual utility values further to extreme
values, we identified 2 utility thresh-
olds. In addition, we also found that
when all surgical utilities were reduced
byat least 24%,medicalmanagementbe-
came preferred. In both of these sensi-
tivity analyses, the postsurgical quality
of life of being seizure free would be
lower than having seizures with medi-
cal treatment and would be inconsis-
tent with the rank ordering of health
states from our patients. If eligible pa-
tients, indeed, felt this way, then sur-
gery would be inappropriate for them.
Fifth, our model consolidates long-
term surgical complications into a single
health state, as was done in the AAN
practice parameter, so it cannot ac-
count in detail for the complex and di-
verse outcomes that occur in individu-
alized patient-physician decision
making, such as potential noticeable
verbal memory decline after surgery of
temporal lobe seizure focus in the lan-
guage dominant hemisphere.
Sixth, our study findings are based
on model projections, derived mostly
from nonrandomized controlled trials
and are subject to potential biases and
flaws associated with those studies.
Decision analysis is a prescriptive ap-
proach to decisionmaking in the face of
uncertainty. It explicitly defines alterna-
tives andoutcomes, and it quantifies un-
certainty to help patients and physi-
cians decide between treatment choices.
By linking the probabilities of becom-
ing or remaining seizure free after treat-
mentwith seizure-relatedmortality rates,
our decision analysis incorporates the
best available data to estimate the long-
term survival consequences of pursu-
ing different treatment choices. For pa-
tients with pharmacoresistant temporal
lobe epilepsy and neurologists, these re-
sults provide an additional perspective
for comparing the relativebenefits of epi-
lepsy surgery vs continuedmedicalman-
agement.
Referral of patients in a timely man-
ner is crucial, because factors such as
older age at surgery and longer dura-
tion of epilepsy are associated with a
lower likelihood of becoming seizure-
free after anterior temporal lobe resec-
tion.61 Referral to a specialized epi-
lepsy surgery program should be
considered when at least 2 appropri-
ate antiepileptic drugs have been tried
at maximum tolerable doses and when
patients are experiencing disabling par-
tial-onset seizures.65 At highly special-
ized epilepsy surgery programs that of-
fer comprehensive diagnostic and
treatment services,66 appropriate pa-
tients for consideration of anterior tem-
poral lobe resections include thosewith
interictal or ictal electroencephalo-
gram finding compatible with mesial
temporal lobe onset seizure, and atro-
phy and signal abnormality of hippo-
campus on brain magnetic resonance
imaging scan on the same side as the
electroencephalogram onset.67 Pa-
tients with discordant findings re-
quire further diagnostic evaluation for
accurate localization of the site of sei-
zure origin.
In conclusion, our findings support
increased use of anterior temporal lobe
resective surgery in appropriate pa-
tients.
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